

Thorsten Verch

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6613716/thorsten-verch-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,148
citations

13
h-index

31
g-index

31
ext. papers

1,289
ext. citations

3.2
avg, IF

3.7
L-index

#	Paper	IF	Citations
30	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. <i>Gynecologic Oncology</i> , 2008 , 108, 402-8	4.9	506
29	Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector. <i>Journal of Immunological Methods</i> , 1998 , 220, 69-75	2.5	117
28	MESOMARK: a potential test for malignant pleural mesothelioma. <i>Clinical Chemistry</i> , 2007 , 53, 666-72	5.5	110
27	Mesothelin variant 1 is released from tumor cells as a diagnostic marker. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1014-20	4	93
26	Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. <i>Infection and Immunity</i> , 2004 , 72, 6418-25	3.7	46
25	Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis. <i>Journal of Pharmacological and Toxicological Methods</i> , 2011 , 63, 227-35	1.7	35
24	2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays). <i>Bioanalysis</i> , 2017 , 9, 1967-1996	2.1	33
23	Immunization with a plant-produced colorectal cancer antigen. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 92-9	7.4	27
22	Replacing antibodies with modified DNA aptamers in vaccine potency assays. <i>Vaccine</i> , 2017 , 35, 5495-5502	2.1	24
21	Miniaturized immunoassays: moving beyond the microplate. <i>Bioanalysis</i> , 2012 , 4, 177-88	2.1	23
20	Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. <i>Technology in Cancer Research and Treatment</i> , 2009 , 8, 323-32	2.7	23
19	Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 1520-6	4	22
18	Development and Characterization of an HPV Type-16 Specific Modified DNA Aptamer for the Improvement of Potency Assays. <i>Analytical Chemistry</i> , 2017 , 89, 3554-3561	7.8	15
17	Pharmacokinetic immunoassay methods in the presence of soluble target. <i>Journal of Immunological Methods</i> , 2010 , 361, 75-81	2.5	13
16	MESOMARK(®) in vitro diagnostic test for mesothelioma. <i>Expert Opinion on Medical Diagnostics</i> , 2007 , 1, 137-42		12
15	Principles of vaccine potency assays. <i>Bioanalysis</i> , 2018 , 10, 163-180	2.1	10
14	Mitigation of microtiter plate positioning effects using a block randomization scheme. <i>Analytical and Bioanalytical Chemistry</i> , 2016 , 408, 3969-79	4.4	9

13	Comparison of the NIDS□ rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics. <i>Journal of Pharmacological and Toxicological Methods</i> , 2011 , 63, 150-9	1.7	6
12	Reduction of dilution error in ELISAs using an internal standard. <i>Bioanalysis</i> , 2016 , 8, 1451-64	2.1	5
11	Quality by design for a vaccine release immunoassay: a case study. <i>Bioanalysis</i> , 2013 , 5, 2531-45	2.1	5
10	Evaluation of a digital dispenser for direct curve dilutions in a vaccine potency assay. <i>Journal of Immunological Methods</i> , 2017 , 442, 20-28	2.5	3
9	Application of quality by design and statistical quality control concepts in immunoassays. <i>Bioanalysis</i> , 2014 , 6, 3251-60	2.1	3
8	Validation of preclinical pharmacokinetic and immunogenicity assays for an anti-PCSK9 antibody. <i>Journal of Immunoassay and Immunochemistry</i> , 2011 , 32, 296-317	1.8	2
7	Anticancer Vaccine Strategies 2008 , 481-511		2
6	Quality-by-Design: As Related to Analytical Concepts, Control and Qualification 2015 , 479-520		1
5	Evaluation of two ELISA methods to detect therapeutic anti-IGF1R antibodies in clinical study samples of dalotuzumab. <i>Bioanalysis</i> , 2011 , 3, 2107-17	2.1	1
4	Analytical Quality by Design, Life Cycle Management, and Method Control.. <i>AAPS Journal</i> , 2022 , 24, 34	3.7	1
3	Monoclonal Antibody Reagent Stability and Expiry Recommendation Combining Experimental Data with Mathematical Modeling. <i>AAPS Journal</i> , 2020 , 22, 145	3.7	1
2	A semi-universal assay platform to quantitate vaccines with potential applications for biotherapeutics. <i>Bioanalysis</i> , 2016 , 8, 2523-2535	2.1	
1	Immunotherapeutic Strategies against Cancer using <i>Listeria monocytogenes</i> as a Vector for Tumor Antigens 2007 , 113-129		